The British journal of ophthalmology · 2026
Paracentral acute middle maculopathy in giant cell arteritis versus non-arteritic anterior ischaemic optic neuropathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hanna Angelica, Dezard Victoria, Namakian Shina, Xie Jim Shenchu, Micieli Jonathan A, Margolin Edward
Аннотация
BACKGROUND/AIMS: To compare the prevalence of paracentral acute middle maculopathy (PAMM) on optical coherence tomography (OCT) in patients with giant cell arteritis (GCA) and non-arteritic anterior ischaemic optic neuropathy (NAION) and to evaluate its association with steroid treatment and presenting visual function.
METHODS: This retrospective observational study included patients with GCA (with or without visual symptoms) and NAION identified from two tertiary care neuro-ophthalmology practices. Clinical data, visual acuity (VA) and visual field mean deviation (VFMD) were collected. OCT imaging was reviewed for the presence of PAMM.
RESULTS: A total of 80 patients with biopsy-proven GCA and 179 patients with NAION were included. PAMM was identified in 28% of patients with GCA versus 0% of patients with NAION (p<0.001). Among patients with GCA, PAMM was observed in 33% of those with persistent visual symptoms, 8% with transient symptoms and 29% without visual symptoms (p=0.23). PAMM was present in 29% of patients who received corticosteroids prior to OCT compared with 22% of those who had not (OR 1.43 (95% CI 0.41 to 4.94); p=0.76). There was no significant association between PAMM and presenting VA or VFMD.
CONCLUSIONS: PAMM occurs in over a quarter of GCA cases but not in NAION, persists after initiation of corticosteroid therapy and can detect subclinical retinal ischaemia in visually asymptomatic patients with normal visual function. These findings support the diagnostic utility of PAMM in differentiating between anterior ischaemic optic neuropathy and NAION and detecting GCA with subclinical ocular involvement.
METHODS: This retrospective observational study included patients with GCA (with or without visual symptoms) and NAION identified from two tertiary care neuro-ophthalmology practices. Clinical data, visual acuity (VA) and visual field mean deviation (VFMD) were collected. OCT imaging was reviewed for the presence of PAMM.
RESULTS: A total of 80 patients with biopsy-proven GCA and 179 patients with NAION were included. PAMM was identified in 28% of patients with GCA versus 0% of patients with NAION (p<0.001). Among patients with GCA, PAMM was observed in 33% of those with persistent visual symptoms, 8% with transient symptoms and 29% without visual symptoms (p=0.23). PAMM was present in 29% of patients who received corticosteroids prior to OCT compared with 22% of those who had not (OR 1.43 (95% CI 0.41 to 4.94); p=0.76). There was no significant association between PAMM and presenting VA or VFMD.
CONCLUSIONS: PAMM occurs in over a quarter of GCA cases but not in NAION, persists after initiation of corticosteroid therapy and can detect subclinical retinal ischaemia in visually asymptomatic patients with normal visual function. These findings support the diagnostic utility of PAMM in differentiating between anterior ischaemic optic neuropathy and NAION and detecting GCA with subclinical ocular involvement.